Phase 3 Hepatitis C Trial Enrollment Complete for Atea Pharmaceuticals
AVIR sits 62% above its 52-week low of $2.78.
Summary
Atea Pharmaceuticals has completed patient enrollment for its Phase 3 C-FORWARD trial, evaluating bemnifosbuvir and ruzasvir for Hepatitis C. This trial enrolled over 880 patients outside North America, marking a significant operational milestone for the company's lead antiviral program. This follows positive Phase 1 results for the same regimen announced in late May, continuing the positive news flow. Topline results from the C-FORWARD trial are expected around year-end 2026, with results from the North American C-BEYOND trial anticipated mid-year 2026.
At the time of this announcement, AVIR was trading at $4.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $358.5M. The 52-week trading range was $2.78 to $6.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.